-
XI CONGRESSO SBBN, Foz do Iguaçu, PR (2016)
Data e Local: 29-8 a 1-9-2016, no Bourbon Cataratas Convention & Spa Resort, Foz do Iguaçu, Paraná. PROGRAMA do XI CONGRESSO SBBN, com objetivos de palestras e cursos e resumos de trabalhos aprovados para painéis: ANAIS DO XI CONGRESSO SBBN_2016 Programa completo da XXXI Reunião Anual da FeSBE (13 sociedades, incluindo o programa do XI Congresso SBBN): fesbe-2016-online-final […]
-
Assine petição FeSBE “on line”: atualização de verbas para pesquisas
Uma nação só se faz grandiosa com investimentos. Infelizmente, a comunidade científica tem sido surpreendida com duros cortes que já comprometem pesquisas e pesquisadores (bolsistas), peças fundamentais para o desenvolvimento tecnológico do país. O orçamento atual do Ministério da Ciência, Tecnologia, Inovações e Comunicações é de R$ 4,6 bilhões, dos quais R$ 500 milhões estão […]
-
Melhores Momentos 2015
[album id=”4″]
-
Melhores Momentos
[album id=”3″]
-
ARCAL CXXXVII: Radiopharmaceuticals for target cancer therapy in Latin America. Prof. René L. Montaña (CENTIS)
The use of radiopharmaceuticals for treatment of cancer is now becoming a reality and there are several new radiopharmaceuticals available in Europe, Asia and North America which uses peptides and antibodies as carrier molecules for targeted therapy using beta emitting particles. Several radioisotopes such as Lu-177, Re-188 and Y-90 are now used for the preparation […]
-
The role of IAEA in Radiopharmacy. Prof. Amir Jalilian (IAEA)
In contrast to other fields, radiopharmacy has been progressed rapidly in last few decades based on the development of new imaging modalities such as PET, PET/CT, PET/MRI and also new production facilities, not only at the research centers and industrial pharmacies, but also at the clinics located at the imaging centers. This has revolutionized the […]
-
Experiences in Radioimmunotherapy in Cuba. Prof. René L. Montaña (IAEA)
The cancer in Cuba constitutes a fundamental problem of health and it occupies the second place as cause of death. It is known that the use of labeled biomolecules (like monoclonal antibodies and peptides) with radioisotopes has become a viable and promissory alternative for the cancer. The monoclonal antibodies production in Cuba for different uses […]
-
Radioactive Gold Nanoparticle in Nanomedicine: Green Nanotechnology and Radiochemical Approaches. Prof. Kattesh V. Katti (Director, Institute of Green Nanotechnology, University of Missouri Cancer Nanotechnology Platform, Missouri, USA)
Radioactive nanoparticles with diagnostic and therapeutic capabilities provide intelligent drug delivery systems to maximize therapeutic activity and to minimize undesirable side-effects. One particularly attractive feature of radioactive gold nanoparticles is that it does not have to be incorporated into every tumor cell to have a therapeutic effect. The path length of the emitted radiation is […]
-
Radioimmunotherapy (RIT) and Peptide Receptor-based Radionuclide Therapy (PRRNT). Prof. René L. Montaña (CENTIS)
With the advent of biotechnological advances and knowledge of molecular and cellular biology, radioimmunotherapy (RIT) has become a highly promising oncologic therapeutic modality with established clinically efficacy, particularly in non-Hodgkin’s lymphomas. A brief review of the published literature on the clinical applications of radioimmunotherapy, is provided. In the other hands a series of radiolabeled peptides […]
-
The choice of radioisotopes for labelling biomolecules. Prof. Amir Jalilian (IAEA)
Radiopharmaceuticals are the main tool in nuclear medicine for diagnosis and therapy of human diseases. Development of new adiopharmaceuticals is based on the clever design of not only the carrier molecules guiding the drug to the target ells/organs but also majorly based on the physicochemical properties of the radionuclides. Beta and recently alpha mitters have […]